Novartis Ag (NVS) EBT (2009 - 2026)
Novartis Ag (NVS) posted EBT of $4.3 billion for Q2 2026, down 5.78% sequentially from $4.5 billion in Q2 2025, and down 5.78% YoY from $4.5 billion in Q2 2025.
Novartis Ag (NVS) EBT (2009 - 2026) Analysis & Trends
Novartis Ag has reported EBT for 18 years, with the latest figure at $4.3 billion in Q2 2026.
- Quarterly EBT fell 5.78% year-over-year to $4.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $19.6 billion (down 4.5% YoY) and the FY2025 annual result came in at $16.4 billion, up 19.88% from the prior year.
- EBT slipped to $4.3 billion in Q2 2026 per NVS's latest filing, from $4.5 billion in the prior quarter.
- Over five years, EBT peaked at $34000.9 billion in Q1 2022 and troughed at $879.0 million in Q3 2022.
- A 5-year average of $3548.8 billion and a median of $4.5 billion in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT soared 142.85% in 2022, then sank 85.29% in 2023.
- Over 5 years, EBT stood at $4.7 billion in 2022, then advanced by 10.25% to $5.2 billion in 2023, then jumped by 34.19% to $7.0 billion in 2024, then slumped by 34.99% to $4.5 billion in 2025, then dropped by 5.78% to $4.3 billion in 2026.
- According to Business Quant data, EBT over the past three periods registered $4.3 billion, $4.5 billion, and $7.0 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 6.75 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 4.28 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -683.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.27 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.80 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.77 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -653.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 474.95 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.27 Bn |
| Jun 30, 2025 | 4.53 Bn |
| Dec 31, 2024 | 6.97 Bn |
| Jun 30, 2024 | 3.84 Bn |
| Dec 31, 2023 | 5.19 Bn |
| Jun 30, 2023 | 2.67 Bn |
| Mar 31, 2023 | 5,000.96 Bn |
| Dec 31, 2022 | 4.71 Bn |
| Sep 30, 2022 | 879.00 Mn |
| Jun 30, 2022 | 2.04 Bn |
| Mar 31, 2022 | 34,000.92 Bn |
| Dec 31, 2021 | 5.96 Bn |
| Sep 30, 2021 | 927.00 Mn |
| Jun 30, 2021 | 3.51 Bn |
| Mar 31, 2021 | 14,000.92 Bn |
| Dec 31, 2020 | 4.91 Bn |
| Sep 30, 2020 | 18,000.91 Bn |
| Jun 30, 2020 | 2.29 Bn |
| Mar 31, 2020 | 194.00 Mn |
| Jun 30, 2019 | 2.63 Bn |